Our findings suggested that combining anti-VEGF signaling pathway agents with immunotherapy, such as immune checkpoint inhibitors (ICI) therapy, may exhibit encouraging benefits in HNSCC. The gene discussed is VEGFA; the disease is head and neck squamous cell carcinoma.